Bal Pharma has launched Favipiravir formulation into Indian market, under the brand name BALflu. Favipiravir is an emerging anti-viral drug used for patients with mild to moderate Covid-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus.
BALflu (Favipiravir) is approved by Drug Controller General of India (DCGI) for emergency use for the treatment of COVID-19 with an recommended dosage of 1800 mg on the first day followed by 800 mg from day 2 to 14.
Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.65 |
| Dr. Reddys Lab | 1220.45 |
| Cipla | 1232.45 |
| Zydus Lifesciences | 929.55 |
| Lupin | 2322.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: